These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24266819)

  • 1. Circulating nucleic acids as biomarkers of prostate cancer.
    Sita-Lumsden A; Fletcher CE; Dart DA; Brooke GN; Waxman J; Bevan CL
    Biomark Med; 2013 Dec; 7(6):867-77. PubMed ID: 24266819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-free nucleic acids as biomarkers in cancer patients.
    Schwarzenbach H; Hoon DS; Pantel K
    Nat Rev Cancer; 2011 Jun; 11(6):426-37. PubMed ID: 21562580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non- PSA serum markers for the diagnosis of PCa].
    Mengual L; Musquera M; Ciudin A; Ribal MJ
    Arch Esp Urol; 2015 Apr; 68(3):229-39. PubMed ID: 25948796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer.
    Mehra N; Penning M; Maas J; van Daal N; Giles RH; Voest EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):421-6. PubMed ID: 17255261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.
    Souza MF; Kuasne H; Barros-Filho MC; Cilião HL; Marchi FA; Fuganti PE; Paschoal AR; Rogatto SR; Cólus IMS
    PLoS One; 2017; 12(9):e0184094. PubMed ID: 28910345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating mRNA signature as a marker for high-risk prostate cancer.
    Souza MF; Kuasne H; Barros-Filho MC; Cilião HL; Marchi FA; Fuganti PE; Rogatto SR; Cólus IMS
    Carcinogenesis; 2020 Apr; 41(2):139-145. PubMed ID: 31305891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease.
    Reis IM; Ramachandran K; Speer C; Gordian E; Singal R
    Br J Cancer; 2015 Jul; 113(3):460-8. PubMed ID: 26171936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of circulating tumor cells in men with localized prostate cancer.
    Seiden MV; Kantoff PW; Krithivas K; Propert K; Bryant M; Haltom E; Gaynes L; Kaplan I; Bubley G; DeWolf W
    J Clin Oncol; 1994 Dec; 12(12):2634-9. PubMed ID: 7527455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
    Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
    Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating biomarkers for prostate cancer.
    Steuber T; Helo P; Lilja H
    World J Urol; 2007 Apr; 25(2):111-9. PubMed ID: 17345087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
    Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
    DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating nucleic acids as a potential source for cancer biomarkers.
    Vlassov VV; Laktionov PP; Rykova EY
    Curr Mol Med; 2010 Mar; 10(2):142-65. PubMed ID: 20196731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis.
    Tóth K; Barták BK; Tulassay Z; Molnár B
    Expert Rev Mol Diagn; 2016; 16(2):239-52. PubMed ID: 26652067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in localized prostate cancer.
    Ferro M; Buonerba C; Terracciano D; Lucarelli G; Cosimato V; Bottero D; Deliu VM; Ditonno P; Perdonà S; Autorino R; Coman I; De Placido S; Di Lorenzo G; De Cobelli O
    Future Oncol; 2016 Feb; 12(3):399-411. PubMed ID: 26768791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNAs as potential new biomarkers for prostate cancer.
    Sita-Lumsden A; Dart DA; Waxman J; Bevan CL
    Br J Cancer; 2013 May; 108(10):1925-30. PubMed ID: 23632485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer.
    Osip'yants AI; Knyazev EN; Galatenko AV; Nyushko KM; Galatenko VV; Shkurnikov MY; Alekseev BY
    Bull Exp Biol Med; 2017 Jan; 162(3):379-382. PubMed ID: 28091918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.
    Gandaglia G; Briganti A; Fossati N; Salonia A; Mottrie A; Catto J; Montorsi F
    Eur Urol; 2016 Oct; 70(4):547-548. PubMed ID: 26916048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus encoded circulatory miRNAs for early detection of prostate cancer.
    Kim J; Yun SJ; Kim WJ
    BMC Urol; 2015 Nov; 15():116. PubMed ID: 26612689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for early prostate cancer detection.
    Margreiter M; Stangelberger A; Valimberti E; Herwig R; Djavan B
    Minerva Urol Nefrol; 2008 Mar; 60(1):51-60. PubMed ID: 18427435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.